Skip to main content
Erschienen in: High Blood Pressure & Cardiovascular Prevention 3/2023

15.04.2023 | Original article

Risk of Incident New-Onset Arterial Hypertension After COVID-19 Recovery: A Systematic Review and Meta-analysis

verfasst von: Marco Zuin, Gianluca Rigatelli, Claudio Bilato, Giampaolo Pasquetto, Alberto Mazza

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Arterial Hypertension (HT) has been described as a common comorbidity and independent risk factor of short-term outcome in COVID-19 patients. However, data regarding the risk of new-onset HT during the post-acute phase of COVID-19 are scant.

Aim

We assess the risk of new-onset HT in COVID-19 survivors within one year from the index infection by a systematic review and meta-analysis of the available data.

Methods

Data were obtained searching MEDLINE and Scopus for all studies published at any time up to February 11, 2023, and reporting the long-term risk of new-onset HT in COVID-19 survivors. Risk data were pooled using the Mantel–Haenszel random effects models with Hazard ratio (HR) as the effect measure with 95% confidence interval (CI). Heterogeneity among studies was assessed using I2 statistic.

Results

Overall, 19,293,346 patients (mean age 54.6 years, 54.6% males) were included in this analysis. Of them, 758,698 survived to COVID-19 infection. Over a mean follow-up of 6.8 months, new-onset HT occurred to 12.7 [95% CI 11.4–13.5] out of 1000 patients survived to COVID-19 infection compared to 8.17 [95% CI 7.34–8.53] out of 1000 control subjects. Pooled analysis revealed that recovered COVID-19 patients presented an increased risk of new-onset HT (HR 1.70, 95% CI 1.46–1.97, p < 0.0001, I2 = 78.9%) within seven months. This risk was directly influenced by age (p = 0.001), female sex (p = 0.03) and cancer (p < 0.0001) while an indirect association was observed using the follow-up length as moderator (p < 0.0001).

Conclusions

Our findings suggest that new-onset HT represents an important post-acute COVID-19 sequelae.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Tadic M, Cuspidi C, Grassi G, Mancia G. COVID-19 and arterial hypertension: hypothesis or evidence? J Clin Hypertens. 2020;22:1120–6.CrossRef Tadic M, Cuspidi C, Grassi G, Mancia G. COVID-19 and arterial hypertension: hypothesis or evidence? J Clin Hypertens. 2020;22:1120–6.CrossRef
2.
Zurück zum Zitat Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020;130:304–9.PubMed Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020;130:304–9.PubMed
3.
Zurück zum Zitat Zuin M, Rigatelli G, Zuliani G, Rigatelli A, Mazza A, Roncon L. Arterial hypertension and risk of death in patients with COVID-19 infection: systematic review and meta-analysis. J Infect. 2020;81:e84–6.CrossRefPubMedPubMedCentral Zuin M, Rigatelli G, Zuliani G, Rigatelli A, Mazza A, Roncon L. Arterial hypertension and risk of death in patients with COVID-19 infection: systematic review and meta-analysis. J Infect. 2020;81:e84–6.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Roncon L, Zuin M, Zuliani G, Rigatelli G. Patients with arterial hypertension and COVID-19 are at higher risk of ICU admission. Br J Anaesth. 2020;125:e254–5.CrossRefPubMed Roncon L, Zuin M, Zuliani G, Rigatelli G. Patients with arterial hypertension and COVID-19 are at higher risk of ICU admission. Br J Anaesth. 2020;125:e254–5.CrossRefPubMed
8.
Zurück zum Zitat Zuin M, Rigatelli G, Battisti V, Costola G, Roncon L, Bilato C. Increased risk of acute myocardial infarction after COVID-19 recovery: a systematic review and meta-analysis. Int J Cardiol. 2023;372:138–43.CrossRefPubMed Zuin M, Rigatelli G, Battisti V, Costola G, Roncon L, Bilato C. Increased risk of acute myocardial infarction after COVID-19 recovery: a systematic review and meta-analysis. Int J Cardiol. 2023;372:138–43.CrossRefPubMed
9.
Zurück zum Zitat Zhang HG, Dagliati A, Shakeri Hossein Abad Z, Xiong X, Bonzel CL, Xia Z, Tan BWQ, Avillach P, Brat GA, Hong C, Morris M, Visweswaran S, Patel LP, Gutiérrez-Sacristán A, Hanauer DA, Holmes JH, Samayamuthu MJ, Bourgeois FT, L’Yi S, Maidlow SE, Moal B, Murphy SN, Strasser ZH, Neuraz A, Ngiam KY, Loh NHW, Omenn GS, Prunotto A, Dalvin LA, Klann JG, Schubert P, Vidorreta FJS, Benoit V, Verdy G, Kavuluru R, Estiri H, Luo Y, Malovini A, Tibollo V, Bellazzi R, Cho K, Ho YL, Tan ALM, Tan BWL, Gehlenborg N, Lozano-Zahonero S, Jouhet V, Chiovato L, Aronow BJ, Toh EMS, Wong WGS, Pizzimenti S, Wagholikar KB, Bucalo M, Consortium for Clinical Characterization of COVID-19 by EHR (4CE), Cai T, South AM, Kohane IS, Weber GM. International electronic health record-derived post-acute sequelae profiles of COVID-19 patients. NPJ Digit Med. 2022;5:81.CrossRefPubMedPubMedCentral Zhang HG, Dagliati A, Shakeri Hossein Abad Z, Xiong X, Bonzel CL, Xia Z, Tan BWQ, Avillach P, Brat GA, Hong C, Morris M, Visweswaran S, Patel LP, Gutiérrez-Sacristán A, Hanauer DA, Holmes JH, Samayamuthu MJ, Bourgeois FT, L’Yi S, Maidlow SE, Moal B, Murphy SN, Strasser ZH, Neuraz A, Ngiam KY, Loh NHW, Omenn GS, Prunotto A, Dalvin LA, Klann JG, Schubert P, Vidorreta FJS, Benoit V, Verdy G, Kavuluru R, Estiri H, Luo Y, Malovini A, Tibollo V, Bellazzi R, Cho K, Ho YL, Tan ALM, Tan BWL, Gehlenborg N, Lozano-Zahonero S, Jouhet V, Chiovato L, Aronow BJ, Toh EMS, Wong WGS, Pizzimenti S, Wagholikar KB, Bucalo M, Consortium for Clinical Characterization of COVID-19 by EHR (4CE), Cai T, South AM, Kohane IS, Weber GM. International electronic health record-derived post-acute sequelae profiles of COVID-19 patients. NPJ Digit Med. 2022;5:81.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.CrossRefPubMedPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Cohen K, Ren S, Heath K, Dasmariñas MC, Jubilo KG, Guo Y, Lipsitch M, Daugherty SE. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2022;376:e068414.CrossRefPubMed Cohen K, Ren S, Heath K, Dasmariñas MC, Jubilo KG, Guo Y, Lipsitch M, Daugherty SE. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2022;376:e068414.CrossRefPubMed
13.
Zurück zum Zitat Daugherty SE, Guo Y, Heath K, Dasmariñas MC, Jubilo KG, Samranvedhya J, Lipsitch M, Cohen K. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373:n1098.CrossRefPubMed Daugherty SE, Guo Y, Heath K, Dasmariñas MC, Jubilo KG, Samranvedhya J, Lipsitch M, Cohen K. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373:n1098.CrossRefPubMed
15.
Zurück zum Zitat Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P, Ekka-Zohar A, Ben David SS, Lerner U, Bivas-Benita M, Greenfeld S. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380:e072529.CrossRefPubMed Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P, Ekka-Zohar A, Ben David SS, Lerner U, Bivas-Benita M, Greenfeld S. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380:e072529.CrossRefPubMed
16.
Zurück zum Zitat Tisler A, Stirrup O, Pisarev H, Kalda R, Meister T, Suija K, Kolde R, Piirsoo M, Uusküla A. Post-acute sequelae of COVID-19 among hospitalized patients in Estonia: Nationwide matched cohort study. PLoS ONE. 2022;17:e0278057.CrossRefPubMedPubMedCentral Tisler A, Stirrup O, Pisarev H, Kalda R, Meister T, Suija K, Kolde R, Piirsoo M, Uusküla A. Post-acute sequelae of COVID-19 among hospitalized patients in Estonia: Nationwide matched cohort study. PLoS ONE. 2022;17:e0278057.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Colangelo LA, Yano Y, Jacobs DR Jr, Lloyd-Jones DM. Association of resting heart rate with blood pressure and Incident Hypertension over 30 years in black and white adults: the CARDIA Study. Hypertension. 2020;76:692–8.CrossRefPubMed Colangelo LA, Yano Y, Jacobs DR Jr, Lloyd-Jones DM. Association of resting heart rate with blood pressure and Incident Hypertension over 30 years in black and white adults: the CARDIA Study. Hypertension. 2020;76:692–8.CrossRefPubMed
18.
Zurück zum Zitat ladin A, Al Rifai M, Rasool S, et al. The association of resting heart rate and Incident Hypertension: the Henry Ford Hospital Exercise Testing (FIT) project. Am J Hypertens. 2016;29:251–7.CrossRef ladin A, Al Rifai M, Rasool S, et al. The association of resting heart rate and Incident Hypertension: the Henry Ford Hospital Exercise Testing (FIT) project. Am J Hypertens. 2016;29:251–7.CrossRef
19.
Zurück zum Zitat Tu K, Chen Z, Lipscombe LL, Canadian Hypertension Education Program Outcomes Research Taskforce. Prevalence and incidence of hypertension from 1995 to 2005: a population-based study. CMAJ. 2008;178:1429–35.CrossRefPubMedPubMedCentral Tu K, Chen Z, Lipscombe LL, Canadian Hypertension Education Program Outcomes Research Taskforce. Prevalence and incidence of hypertension from 1995 to 2005: a population-based study. CMAJ. 2008;178:1429–35.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Kent ST, Schwartz JE, Shimbo D, Overton ET, Burkholder GA, Oparil S, Mugavero MJ, Muntner P. Race and sex differences in ambulatory blood pressure measures among HIV + adults. J Am Soc Hypertens. 2017;11:420–427e3.CrossRefPubMedPubMedCentral Kent ST, Schwartz JE, Shimbo D, Overton ET, Burkholder GA, Oparil S, Mugavero MJ, Muntner P. Race and sex differences in ambulatory blood pressure measures among HIV + adults. J Am Soc Hypertens. 2017;11:420–427e3.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Asgari S, Moazzeni SS, Azizi F, Abdi H, Khalili D, Hakemi MS, Hadaegh F. Sex-specific incidence rates and risk factors for hypertension during 13 years of follow-up: the Tehran lipid and glucose study. Glob Heart. 2020;15:29.CrossRefPubMedPubMedCentral Asgari S, Moazzeni SS, Azizi F, Abdi H, Khalili D, Hakemi MS, Hadaegh F. Sex-specific incidence rates and risk factors for hypertension during 13 years of follow-up: the Tehran lipid and glucose study. Glob Heart. 2020;15:29.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Ogungbe O, Gilotra NA, Davidson PM. Et alCardiac postacute sequelae symptoms of SARS-CoV-2 in community-dwelling adults: cross-sectional. studyOpen Heart. 2022;9:e002084. Ogungbe O, Gilotra NA, Davidson PM. Et alCardiac postacute sequelae symptoms of SARS-CoV-2 in community-dwelling adults: cross-sectional. studyOpen Heart. 2022;9:e002084.
23.
26.
Zurück zum Zitat Annweiler Z, Cao Y, Wu E, Faucon S, Mouhat H, Kovacic J, Sabatier M. Counter-regulatory ‘renin-Angiotensin’ systemBased candidate drugs to treat COVID-19 diseases in SARS-CoV-2-Infected patients. Infect Disord -Drug Targets. 2020;20:407–8.PubMed Annweiler Z, Cao Y, Wu E, Faucon S, Mouhat H, Kovacic J, Sabatier M. Counter-regulatory ‘renin-Angiotensin’ systemBased candidate drugs to treat COVID-19 diseases in SARS-CoV-2-Infected patients. Infect Disord -Drug Targets. 2020;20:407–8.PubMed
27.
Zurück zum Zitat Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626–38.CrossRefPubMed Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626–38.CrossRefPubMed
29.
Zurück zum Zitat Ruzzenenti G, Maloberti A, Giani V, Biolcati M, Leidi F, Monticelli M, Grasso E, Cartella I, Palazzini M, Garatti L, Ughi N, Rossetti C, Epis OM, Giannattasio C, Covid-19 Niguarda Working Group. Covid and cardiovascular diseases: direct and indirect damages and future perspective. High Blood Press Cardiovasc Prev. 2021;28:439–45.CrossRefPubMedPubMedCentral Ruzzenenti G, Maloberti A, Giani V, Biolcati M, Leidi F, Monticelli M, Grasso E, Cartella I, Palazzini M, Garatti L, Ughi N, Rossetti C, Epis OM, Giannattasio C, Covid-19 Niguarda Working Group. Covid and cardiovascular diseases: direct and indirect damages and future perspective. High Blood Press Cardiovasc Prev. 2021;28:439–45.CrossRefPubMedPubMedCentral
Metadaten
Titel
Risk of Incident New-Onset Arterial Hypertension After COVID-19 Recovery: A Systematic Review and Meta-analysis
verfasst von
Marco Zuin
Gianluca Rigatelli
Claudio Bilato
Giampaolo Pasquetto
Alberto Mazza
Publikationsdatum
15.04.2023
Verlag
Springer International Publishing
Erschienen in
High Blood Pressure & Cardiovascular Prevention / Ausgabe 3/2023
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI
https://doi.org/10.1007/s40292-023-00574-5

Weitere Artikel der Ausgabe 3/2023

High Blood Pressure & Cardiovascular Prevention 3/2023 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.